ICU to boost critical care line with Hospira deal
This article was originally published in Clinica
Executive Summary
In a bid to focus on its core technologies, specialty pharmaceutical and medication delivery firm Hospira is to divest its critical care product line to ICU Medical in a $35m cash deal. The transaction, which is expected to close during the third quarter of 2009, is part of Hospira’s plan to focus on its injectable pharmaceuticals and medication management systems. ICU had previously been the manufacturer of Hospira’s critical care offering, which includes invasive vascular and cardiac monitoring systems, angiography kits and Transpac disposable pressure transducers, since the two firms struck a manufacturing, commercialisation and development agreement in 2005. ICU claims that the deal will be accretive to earnings in fiscal 2009.